• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying

    7/25/24 9:12:19 AM ET
    $ATYR
    $RVP
    $SLE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ATYR alert in real time by email

    The Dow Jones index closed lower by over 500 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

    Super League Enterprise

    • The Trade: Super League Enterprise, Inc. (NASDAQ:SLE) Director Jeff Patrick Gehl bought a total of 50,000 shares at an average price of $1.35. To acquire these shares, it cost around $67,548.
    • What's Happening: On June 21, Super League issued a mid-year update from the Company's Chief Executive Office, Ann Hand.
    • What Super League Enterprise Does: Super League Enterprise Inc is the rocket ship to the metaverse.

    aTyr Pharma

    • The Trade: aTyr Pharma, Inc. (NASDAQ:ATYR) Director Paul Schimmel acquired a total of 100,000 shares at an average price of $1.85. To acquire these shares, it cost around $184,613.
    • What's Happening: On July 22, HC Wainwright & Co. analyst Joseph Pantginis reiterated aTyr Pharma with a Buy rating and maintained a $35 price target.
    • What aTyr Pharma Does: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.

    Retractable Technologies

    • The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw acquired a total of 8,788 shares at an average price of $1.09. The insider spent around $9,579 to buy those shares.
    • What's Happening: On May 15, Retractable Technologies posted a decline in quarterly sales results.
    • What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.

    Read Next:

    • Nasdaq, S&P 500 Record Worst Session Since 2022 Amid Tesla, Alphabet Selloff: Investor Optimism Decreases Further
    Get the next $ATYR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATYR
    $RVP
    $SLE

    CompanyDatePrice TargetRatingAnalyst
    Super League Enterprise Inc.
    $SLE
    11/10/2025$5.00Buy
    Aegis Capital
    aTyr Pharma Inc.
    $ATYR
    9/16/2025$1.50Outperform → Sector Perform
    RBC Capital Mkts
    aTyr Pharma Inc.
    $ATYR
    9/15/2025$1.00Overweight → Equal Weight
    Wells Fargo
    aTyr Pharma Inc.
    $ATYR
    9/15/2025Buy → Neutral
    H.C. Wainwright
    aTyr Pharma Inc.
    $ATYR
    9/15/2025$1.00Outperform → Market Perform
    Leerink Partners
    aTyr Pharma Inc.
    $ATYR
    9/15/2025Overweight → Neutral
    Cantor Fitzgerald
    aTyr Pharma Inc.
    $ATYR
    2/18/2025$16.00Outperform
    Leerink Partners
    aTyr Pharma Inc.
    $ATYR
    1/6/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ATYR
    $RVP
    $SLE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

    Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis.  Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) on track to complete enrollment in the first half of 2026. Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase pla

    3/5/26 4:01:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 12,200 shares of aTyr's common stock, each with an exercise price of $0.98 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on February 17, 2026, the effective date of the grants. These stock awards were granted as an inducement ma

    2/20/26 4:01:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

    SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference, which is scheduled to take place March 8 – 11, 2026, in Miami, FL. Details of the presentation appear below: Conference: Leerink Partners Global Healthcare ConferenceDate: Wednesday, March 11, 2026Time: 8:00am EDTLocation: Miami, FLFormat: Corporate Presentation In addition to the presentation, company m

    2/18/26 8:00:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    $RVP
    $SLE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Patrick Kristin increased direct ownership by 3,490% to 2,477 units (SEC Form 5)

    5 - Super League Enterprise, Inc. (0001621672) (Issuer)

    3/3/26 9:06:21 AM ET
    $SLE
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Gehl Jeff Patrick increased direct ownership by 294% to 1,289 units (SEC Form 5)

    5 - Super League Enterprise, Inc. (0001621672) (Issuer)

    2/17/26 1:55:07 PM ET
    $SLE
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Jung Mark increased direct ownership by 237% to 3,426 units (SEC Form 5)

    5 - Super League Enterprise, Inc. (0001621672) (Issuer)

    2/17/26 1:54:04 PM ET
    $SLE
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $ATYR
    $RVP
    $SLE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Shaw Thomas J bought $4,424 worth of shares (5,731 units at $0.77), increasing direct ownership by 0.04% to 15,831,222 units (SEC Form 4)

    4 - RETRACTABLE TECHNOLOGIES INC (0000946563) (Issuer)

    11/17/25 11:29:38 AM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND CEO Shaw Thomas J bought $81 worth of shares (100 units at $0.81), increasing direct ownership by 0.00% to 15,825,491 units (SEC Form 4)

    4 - RETRACTABLE TECHNOLOGIES INC (0000946563) (Issuer)

    11/13/25 1:29:23 PM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND CEO Shaw Thomas J bought $6,195 worth of shares (7,500 units at $0.83), increasing direct ownership by 0.05% to 15,825,391 units (SEC Form 4)

    4 - RETRACTABLE TECHNOLOGIES INC (0000946563) (Issuer)

    11/6/25 10:53:09 AM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    $ATYR
    $RVP
    $SLE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital initiated coverage on Super League Enterprise with a new price target

    Aegis Capital initiated coverage of Super League Enterprise with a rating of Buy and set a new price target of $5.00

    11/10/25 8:47:14 AM ET
    $SLE
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    aTyr Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded aTyr Pharma from Outperform to Sector Perform and set a new price target of $1.50

    9/16/25 8:00:57 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded aTyr Pharma from Overweight to Equal Weight and set a new price target of $1.00

    9/15/25 1:24:32 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    $RVP
    $SLE
    SEC Filings

    View All

    SEC Form 10-K filed by aTyr Pharma Inc.

    10-K - aTYR PHARMA INC (0001339970) (Filer)

    3/5/26 4:11:20 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - aTYR PHARMA INC (0001339970) (Filer)

    3/5/26 4:03:40 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Super League Enterprise Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Super League Enterprise, Inc. (0001621672) (Filer)

    1/28/26 4:51:57 PM ET
    $SLE
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $ATYR
    $RVP
    $SLE
    Leadership Updates

    Live Leadership Updates

    View All

    Super League Appoints Marti Frucci, Investment Banking Veteran, to Board of Directors

    ~ Appointment Enhances Capital Markets Expertise to Support Growth Following Balance Sheet Strengthening ~    SANTA MONICA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Super League (NASDAQ:SLE) (the "Company"), a leader in playable media trusted by global brands to reach and activate gaming audiences through playable ads and gamified content, announced today the appointment of Marti Frucci to its Board of Directors, effective January 1, 2026. Additionally, Chief Executive Officer Matt Edelman will assume the role of Chairman of the Board, effective January 1, 2026. Ms. Frucci, Founder and Managing Partner of Momentum Ventures Advisory, is a highly experienced investment banking professiona

    1/6/26 9:45:00 AM ET
    $SLE
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

    SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies, including leading rare disease product launches. She will serve as a member of the Company's executive leadership team, overseeing global commercial strategy and operations for the efzofitimod prog

    3/26/25 8:00:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

    SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company's Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). "We are excited to welcome Eric Benevich to the Board of Directors," said Timothy P. Coughlin, Chairman of the Board of aTyr. "His extensive background bringing new products to market and the knowledge and experti

    12/12/24 4:00:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    $RVP
    $SLE
    Financials

    Live finance-specific insights

    View All

    Super League Acquires Let's Bounce, Inc. to Accelerate Full Funnel Marketing within Gaming and UGC Channels

    Marketing Tech Platform Expands Capabilities Across Turnkey In-Game Activations, Loyalty Mechanics and Campaign Measurement SANTA MONICA, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Super League (NASDAQ:SLE) (the "Company"), a leader in playable media trusted by global brands to reach and activate gaming audiences through playable ads and gamified content, announced today the acquisition of Let's Bounce, Inc. ("Bounce"), a marketing technology company focused on enabling scalable, measurable brand engagement inside gaming and UGC environments. Bounce, with an existing pipeline of opportunities, is expected to have an immediate positive impact on Super League's path to profitability and abil

    1/7/26 9:00:00 AM ET
    $RBLX
    $SLE
    Computer Software: Prepackaged Software
    Technology
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Super League Acquires Stake in Top 100 Roblox Game: Hide or Die!

    Execution of Ownership Strategy to Drive High Margin Growth and Expand Brand Partnership Revenues  SANTA MONICA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Super League (NASDAQ:SLE) (the "Company"), a leader in playable media trusted by global brands to reach and activate gaming audiences through playable ads and gamified content, announced today it has acquired an interest in Hide or Die!, a Top 100 Roblox game (source: Rotrends) that has been visited more than 570 million times in 16 months. The investment reflects a transition from strategy to execution as the Company begins securing ownership positions in cash-generating assets within the gaming content and media economy, establishing

    1/6/26 9:00:00 AM ET
    $RBLX
    $SLE
    Computer Software: Prepackaged Software
    Technology
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders

    Retractable Technologies, Inc. ("Retractable") (NYSE:RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends cover the period beginning October 1, 2025 through December 31, 2025. The dividends will be paid on January 20, 2026 to shareholders of record as of the close of business on January 10, 2026. Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and

    12/30/25 4:14:00 PM ET
    $RVP
    Medical/Dental Instruments
    Health Care

    $ATYR
    $RVP
    $SLE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by aTyr Pharma Inc.

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    11/14/24 6:51:17 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Super League Enterprise Inc.

    SC 13D - Super League Enterprise, Inc. (0001621672) (Subject)

    11/1/24 5:00:13 PM ET
    $SLE
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by Super League Enterprise Inc.

    SC 13G - Super League Enterprise, Inc. (0001621672) (Subject)

    10/24/24 5:20:52 PM ET
    $SLE
    Services-Misc. Amusement & Recreation
    Consumer Discretionary